Clostridium Botulinum Infections - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 39

Clostridium Botulinum Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Clostridium Botulinum Infections - Pipeline Review, H2 2012', provides an overview of the Clostridium Botulinum Infections therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Botulinum Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Botulinum Infections. 'Clostridium Botulinum Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Clostridium Botulinum Infections.
- A review of the Clostridium Botulinum Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Clostridium Botulinum Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Clostridium Botulinum Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Clostridium Botulinum Infections pipeline depth and focus of Clostridium Botulinum Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Clostridium Botulinum Infections Therapeutic Products under Development, Key Players in Clostridium Botulinum Infections Therapeutics, Clostridium Botulinum Infections Pipeline Overview, Clostridium Botulinum Infections Pipeline, Clostridium Botulinum Infections Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Clostridium Botulinum Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Clostridium Botulinum Infections 7
Clostridium Botulinum Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Clostridium Botulinum Infections Therapeutics – Products under Development by Companies 14
Companies Involved in Clostridium Botulinum Infections Therapeutics Development 15
Emergent BioSolutions Inc. 15
Cangene Corporation 16
XOMA Ltd. 17
Morphotek, Inc. 18
AlphaVax, Inc. 19
DynPort Vaccine Company LLC 20
Molecular Targeting Technologies, Inc. 21
Clostridium Botulinum Infections – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
MORAb-047 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Recombinant Botulinum Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Botulinum Toxin Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
XOMA 3AB - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Botulism Antitoxin Heptavalent - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
rBV A/B - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Botulinum Toxin Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Clostridium Botulinum Infections Therapeutics – Drug Profile Updates 36
Clostridium Botulinum Infections – Product Development Milestones 37
Featured News & Press Releases 37
May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Clostridium Botulinum Infections, H2 2012 7
Products under Development for Clostridium Botulinum Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Emergent BioSolutions Inc., H2 2012 15
Cangene Corporation, H2 2012 16
XOMA Ltd., H2 2012 17
Morphotek, Inc., H2 2012 18
AlphaVax, Inc., H2 2012 19
DynPort Vaccine Company LLC, H2 2012 20
Molecular Targeting Technologies, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Clostridium Botulinum Infections Therapeutics – Drug Profile Updates 36

List of Figures
Number of Products under Development for Clostridium Botulinum Infections, H2 2012 7
Products under Development for Clostridium Botulinum Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Customers who bought this item also bought

• Community-Acquired Infections – Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Hospital-Treated Infections (Event Driven)
• Fungal Infections – Pipeline Review, H1 2013
• Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma
• Global Pneumococcal Infections Drug Pipeline Capsule - 2012
• 2012 Global Clostridium Diagnostics Market Outlook: Test Volume and Sales Forecasts by Country and Market Segment
• Foodborne Infections and Intoxications. Edition No. 4. Food Science and Technology